US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chemomab Therapeutics Ltd.

1.42

+0.05003.65%

Volume:138.92K

Turnover:194.55K

Market Cap:26.78M

PE:-1.83

High:1.43

Open:1.36

Low:1.35

Close:1.37

Loading ...

Overview Company News Filings

Biotech Alert: Searches spiking for these stocks today

Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment

MT Newswires Live

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer

MT Newswires Live

Chemomab Announces New Medical and Clinical Appointments

BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers

Chemomab Therapeutics Ltd - Treatment for up to 48 Weeks Was Well-Tolerated

THOMSON REUTERS

Chemomab Therapeutics- Reinforces and Expands Positive Results From 15-Week Double-Blind Phase 2 Spring Trial

THOMSON REUTERS

Chemomab Reports Positive Results in Nebokitug Phase 2 Psc Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

THOMSON REUTERS

Press Release: American Public Education, Inc. Appoints Richard J. Statuto to its Board of Directors

Chemomab Therapeutics announces new scientific presentation on nebokitug

Chemomab Therapeutics Ltd reports results for the quarter ended December 31 - Earnings Summary

Chemomab Therapeutics (CMMB) Gets a Buy from Oppenheimer

Chemomab Therapeutics Q4 EPS $(0.008) vs $(0.013) YoY

Chemomab Therapeutics Q4 Operating Expenses USD 3.213 Million

THOMSON REUTERS

Chemomab Therapeutics Ltd: Q4 Shr Loss Less Than $0.01

THOMSON REUTERS

Chemomab Therapeutics Ltd expected to post a loss of 8 cents a share - Earnings Preview

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns With FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (Cm-101) in Primary Sclerosing Cholangitis

THOMSON REUTERS

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CMMB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CMMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMMB\",,,,,undefined,":{"symbol":"CMMB","market":"US","secType":"STK","nameCN":"Chemomab Therapeutics Ltd.","latestPrice":1.42,"timestamp":1746216000000,"preClose":1.37,"halted":0,"volume":138917,"delay":0,"floatShares":13086340,"shares":18856611,"eps":-0.776774,"marketStatus":"Pre-Mkt","change":0.05,"latestTime":"05-05 06:55:30 EDT","open":1.36,"high":1.43,"low":1.3515,"amount":194547.473,"amplitude":0.057299,"askPrice":1.59,"askSize":100,"bidPrice":1.2,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.776774,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746451800000},"marketStatusCode":1,"adr":0,"adrRate":20,"listingDate":1549947600000,"exchange":"NASDAQ","adjPreClose":1.42,"postHourTrading":{"tag":"盘后","latestPrice":1.4001,"preClose":1.42,"latestTime":"19:37 EDT","volume":9532,"amount":13394.082,"timestamp":1746229048368},"volumeRatio":1.2219124118912645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMMB\",,,,,undefined,":{"symbol":"CMMB","floatShares":13086340,"roa":"-47.10%","roe":"-91.34%","lyrEps":-0.776774,"volumeRatio":1.2219124118912645,"shares":18856611,"dividePrice":0,"high":1.43,"amplitude":0.057299,"preClose":1.37,"low":1.3515,"week52Low":0.603,"pbRate":"1.98","week52High":2.55,"institutionHeld":0,"latestPrice":1.42,"committee":0.333333,"eps":-0.776774,"divideRate":0,"volume":138917,"delay":0,"ttmEps":-0.776774,"open":1.36,"prevYearClose":1.81,"prevWeekClose":1.42,"prevMonthClose":1.35,"prevQuarterClose":1.09,"fiveDayClose":1.31,"twentyDayClose":1.07,"sixtyDayClose":2.08},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CMMB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532000582","title":"Biotech Alert: Searches spiking for these stocks today","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000582","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000582?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:15","pubTimestamp":1746116123,"startTime":"0","endTime":"0","summary":"These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:. Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter.Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.Tevogen Bio Holdings , 332% surge in interest. Pipeline and key clinical candidates for these companies:. Galmed is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. The company has focused almost exclusively on developing Aramchol for the treatment of noncirrhotic nonalcoholic steatohepatitis, or NASH, and are currently developing Aramchol for Primary Sclerosing Cholangitis, or PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease.CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJJMRZ35.SGD","SNTI","IE00B4R5TH58.HKD","SWTX","IE00BJT1NW94.SGD","TVGN","BK4539","IE00B2B36J28.USD","RGLS","BK4532","BK4578","BK4588","GLMD","CMMB","IE00BFTCPJ56.SGD","BK4585","MKKGY","IE0002141913.USD","CGON","IE0009355771.USD","LU0320765489.SGD","BCDAW","BK4139","LU0211331839.USD","LU0070302665.USD","LU0208291251.USD","BK4007","NVS","TVGNW","BCDA"],"gpt_icon":0},{"id":"2531925815","title":"Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2531925815","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531925815?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:17","pubTimestamp":1745860632,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics  reported positive results from a Phase 2 trial of nebokitug, a treatment for primary sclerosing cholangitis and other fibro-inflammatory diseases.Patients treated with nebokitug exhibited significant changes in several proteins associated with fibrosis, inflammation and immune system activity with the effects increasing at higher doses, the company said Monday in a statement.The data showed that the nebokitug treatment reduced biological processes tied to fibrosis and inflammation, the company said.Nebokitug also lowered proteins involved in immune cell movement, inflammatory signals and collagen binding, the company said.Shares of the company rose 1.5% in recent Monday trading.Price: 1.33, Change: +0.02, Percent Change: +1.53","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","LENZ","CMMB"],"gpt_icon":0},{"id":"2530409113","title":"Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2530409113","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530409113?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers. Further Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Other Fibro-Inflammatory Conditions. Second EASL 2025 Poster Reports that Pharmacokinetic and Pharmacodynamic Data from the Phase 2 Spring Trial Demonstrates Effective and Dose-Dependent Antibody-Target Engagement. The second abstract presents an analysis of the pharmacodynamics and pharmacokinetics  of nebokitug and CCL24 using patient data from the Phase 2 SPRING trial in patients with PSC.2 PK analyses indicated dose-proportional increases in the concentration of nebokitug with steady-state","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-reports-positive-clinical-data-120000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMMB","BK4139","PSC","PK","BK4218","BK4181"],"gpt_icon":0},{"id":"2529806511","title":"Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2529806511","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529806511?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:00","pubTimestamp":1745236800,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, April 21, 2025  -- Chemomab Therapeutics, Ltd., , a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug  for the treatment of patients with primary sclerosing cholangitis  will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25, the British Society of Gastroenterology’s annual meeting. Chemomab will report information on the content of the presentations after the meeting embargoes lift.Oral presentation: CM-101, a novel monoclonal antibody targeting CCL24, was safe, well-tolerated and showed improvements of biomarkers associated with inflammation, fibrosis and cholestasis in patients with primary sclerosing cholangitis : The Spring Study. Paul Pockros, MD, Director, Liver Disease Scripps Clinic and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-therapeutics-present-nebokitug-clinical-120000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSC","LENZ","BK4139","CMMB","BK4007"],"gpt_icon":0},{"id":"2527446927","title":"Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527446927","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527446927?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:52","pubTimestamp":1744728774,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics  said Tuesday it has named David Weiner as interim chief medical officer, succeeding Matt Frankel.Weiner was interim CMO at Chemomab in 2021-2022 and has been a consultant to the company in the years since, the company said.Additionally, Jack Lawler, senior vice president of global medical operations at Chemomab, was appointed as chief development officer, the company said. Lawler joined Chemomab in 2022.Price: 1.17, Change: -0.03, Percent Change: -2.50","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMMB","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2527490299","title":"Chemomab Announces New Medical and Clinical Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2527490299","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527490299?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience. Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial inPSC, Assumes Chief Development Officer Role. Dr. Weiner commented, “I welcome the opportunity to rejoin Chemomab at this exciting time for the company. We have reported compelling clinical proof-of-concept data showing that nebokitug has the potential to become the first FDA-approved drug for PSC with disease-modifying activity and that it also may have potential in other fibro-inflammatory diseases. These are challenging times for o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-announces-medical-clinical-appointments-120000196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSC","BK4139","CMMB"],"gpt_icon":0},{"id":"2522370225","title":"BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers","url":"https://stock-news.laohu8.com/highlight/detail?id=2522370225","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522370225?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:32","pubTimestamp":1743078761,"startTime":"0","endTime":"0","summary":"BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver BiomarkersMarch 27 (Reuters) - Chemomab Th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA8QKXZ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB","BK4139"],"gpt_icon":0},{"id":"2522370181","title":"Chemomab Therapeutics Ltd - Treatment for up to 48 Weeks Was Well-Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2522370181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522370181?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:30","pubTimestamp":1743078601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA8QKXZ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMMB"],"gpt_icon":0},{"id":"2522370136","title":"Chemomab Therapeutics- Reinforces and Expands Positive Results From 15-Week Double-Blind Phase 2 Spring Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2522370136","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522370136?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:30","pubTimestamp":1743078601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA8QKXZ5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMMB","BK4139"],"gpt_icon":0},{"id":"2522337015","title":"Chemomab Reports Positive Results in Nebokitug Phase 2 Psc Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers","url":"https://stock-news.laohu8.com/highlight/detail?id=2522337015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522337015?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:30","pubTimestamp":1743078601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA8QKXZ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMMB"],"gpt_icon":0},{"id":"2517820435","title":"Press Release: American Public Education, Inc. Appoints Richard J. Statuto to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2517820435","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517820435?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:58","pubTimestamp":1741355880,"startTime":"0","endTime":"0","summary":"A Former Health System CEO, Mr. Statuto Has Over 30 Years of Leadership Experience. CHARLES TOWN, W.V., March 7, 2025 /PRNewswire/ -- American Public Education, Inc.  today announced it has appointed Richard J. Statuto, an accomplished health system CEO, to its Board of Directors, effective March 6, 2025. The appointment brings the total number of APEI board members to nine.Mr. Statuto, currently Chairman of the Board of Directors at Charlotte, N.C.-based Premier, Inc., also previously served as President and CEO of Bon Secours Health System, one of the largest health systems in the United States, for 13 years. Prior to that, he was CEO of St. Joseph Health System for nine years. Both health systems exceeded $3 billion in revenue and were highly profitable.\"We are excited to welcome Rich to APEI's Board of Directors,\" said Ric Andersen, Chairman of APEI's Board of Directors. \"His impressive experience driving growth at large health systems aligns well with APEI's strategy and future ob","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APEI","BK4204","BK4139","CMMB"],"gpt_icon":0},{"id":"2517015227","title":"Chemomab Therapeutics announces new scientific presentation on nebokitug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517015227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517015227?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:11","pubTimestamp":1741266674,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics (CMMB) announced a new scientific presentation that further confirms the potential of nebokitug as a novel treatment for syst...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/chemomab-therapeutics-announces-new-scientific-presentation-on-nebokitug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/chemomab-therapeutics-announces-new-scientific-presentation-on-nebokitug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","CMMB"],"gpt_icon":0},{"id":"2517919184","title":"Chemomab Therapeutics Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919184","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517919184?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:01","pubTimestamp":1741179701,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd reports results for the quarter ended December 31 - Earnings SummaryChemomab Therapeutics Ltd CMMB.OQ reported a quarterly adjusted loss of 1 cent per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL5N3PO16T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB"],"gpt_icon":0},{"id":"2516679387","title":"Chemomab Therapeutics (CMMB) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516679387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516679387?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:15","pubTimestamp":1741094141,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jeff Jones reiterated a Buy rating on Chemomab Therapeutics (CMMB – Research Report) today and set a price target of $11.00. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chemomab-therapeutics-cmmb-gets-a-buy-from-oppenheimer-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chemomab-therapeutics-cmmb-gets-a-buy-from-oppenheimer-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","CMMB","BK4139","BK4127"],"gpt_icon":0},{"id":"2516633010","title":"Chemomab Therapeutics Q4 EPS $(0.008) vs $(0.013) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633010","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516633010?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:10","pubTimestamp":1741007432,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Q4 EPS $(0.008) vs $(0.013) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44075371/chemomab-therapeutics-q4-eps-0-008-vs-0-013-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CMMB"],"gpt_icon":0},{"id":"2516633677","title":"Chemomab Therapeutics Q4 Operating Expenses USD 3.213 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516633677?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nPLX8C279C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMMB"],"gpt_icon":0},{"id":"2516633150","title":"Chemomab Therapeutics Ltd: Q4 Shr Loss Less Than $0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516633150?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nPLX8C279C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMMB"],"gpt_icon":0},{"id":"2516468719","title":"Chemomab Therapeutics Ltd  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2516468719","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516468719?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:02","pubTimestamp":1741003374,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd  expected to post a loss of8cents a share - Earnings Preview Chemomab Therapeutics Ltd CMMB.OQ CMMB.O is expected to show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL5N3PM0RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB"],"gpt_icon":0},{"id":"2512939105","title":"Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns With FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (Cm-101) in Primary Sclerosing Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2512939105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512939105?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:00","pubTimestamp":1739966400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA6Z4VGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMMB"],"gpt_icon":0},{"id":"2512051221","title":"Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2512051221","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512051221?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:00","pubTimestamp":1739966400,"startTime":"0","endTime":"0","summary":"Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved Treatment for PSC. No Liver Biopsies or Additional Confirmatory Studies Required—Phase 3 Trial Endpoint Is Based onWell-Characterized Clinical Events Associated with PSC Disease Progression. Advancing Discussions with Potential Strategic Partners Post-FDA Feedback While Preparingfor Nebokitug Phase 3 Trial. Dr. Mor continued, “Importantly, key publications have shown that the reductions in PSC biomarkers in our nebokitug Phase 2 SPRING trial, especially the Enhanced Liver Fibrosis  and liver stiffness elastography measures, are associated with reductions in clinical events, increasing our confidence in the relevance of this approach for nebokitug and decreasing risk. We are looking forward to reporting topline data from the open label extension portion of the SPRING trial, which is prima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-completes-successful-end-phase-120000353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1242518931.SGD","PSC","BK4207","INN","BK4183","CM","BK4218","BK4585","CMMB","BK4139","ELF","LU1559883803.SGD","LU0566484027.USD","LU1242518857.USD","BK4181","LU0979878070.USD","BK4588","LU0053671581.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CMMB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-03","symbol":"CMMB","fiscalQuarterEnding":"2024/12","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-0.16},{"market":"US","date":"2024-11-14","symbol":"CMMB","fiscalQuarterEnding":"2024/09","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2024-08-21","symbol":"CMMB","fiscalQuarterEnding":"2024/06","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1724212800000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2024-05-09","symbol":"CMMB","fiscalQuarterEnding":"2024/03","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.28},{"market":"US","date":"2024-03-07","symbol":"CMMB","fiscalQuarterEnding":"2023/12","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1709787600000,"reportTimeType":"pre","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CMMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CMMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1715659200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CMMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CMMB","date":"2025-05-02","current":-1.852532,"percent":0.458624,"low":-98.872227,"twenty":-8.369248,"median":-1.55589,"eighty":-0.487258,"high":58.769136,"avg":-6.876782,"sd":13.734891,"marketCap":25833557},"quantilePoints":[{"date":"2021-03-19","current":-91.519729,"twenty":-35.539936,"median":48.429753,"eighty":54.633383,"marketCap":544633907},{"date":"2021-03-26","current":-55.781913,"twenty":-75.955442,"median":-57.552625,"eighty":6.745087,"marketCap":331958164},{"date":"2021-04-01","current":-50.766395,"twenty":-63.6845,"median":-54.253888,"eighty":-50.935377,"marketCap":302110814},{"date":"2021-04-09","current":-82.513368,"twenty":-79.007898,"median":-52.725862,"eighty":-48.975909,"marketCap":491037052},{"date":"2021-04-16","current":-49.004772,"twenty":-71.281483,"median":-56.204367,"eighty":-49.19171,"marketCap":291627398},{"date":"2021-04-23","current":-61.121139,"twenty":-69.57369,"median":-56.626821,"eighty":-50.104849,"marketCap":363731898},{"date":"2021-04-30","current":-53.139437,"twenty":-64.691225,"median":-57.669532,"eighty":-50.935377,"marketCap":316232791},{"date":"2021-05-07","current":-35.648005,"twenty":-63.397002,"median":-55.781913,"eighty":-48.78897,"marketCap":212141280},{"date":"2021-05-14","current":-30.514421,"twenty":-62.857698,"median":-53.74166,"eighty":-36.852451,"marketCap":181865949},{"date":"2021-05-21","current":-31.196508,"twenty":-62.433446,"median":-51.73714,"eighty":-34.423856,"marketCap":185931187},{"date":"2021-05-28","current":-31.770897,"twenty":-61.919309,"median":-50.550725,"eighty":-31.311386,"marketCap":189354546},{"date":"2021-06-04","current":-32.452984,"twenty":-61.588536,"median":-49.472118,"eighty":-30.848198,"marketCap":193419785},{"date":"2021-06-11","current":-42.935585,"twenty":-61.570559,"median":-46.829482,"eighty":-31.196508,"marketCap":255896088},{"date":"2021-06-18","current":-38.104027,"twenty":-61.121139,"median":-42.083702,"eighty":-31.250357,"marketCap":227100000},{"date":"2021-06-25","current":-38.307101,"twenty":-60.366113,"median":-41.39013,"eighty":-31.770897,"marketCap":228310320},{"date":"2021-07-02","current":-34.76254,"twenty":-58.478428,"median":-40.587065,"eighty":-32.322296,"marketCap":207184738},{"date":"2021-07-09","current":-34.984075,"twenty":-57.184194,"median":-39.848616,"eighty":-32.29343,"marketCap":208505087},{"date":"2021-07-16","current":-33.839477,"twenty":-56.673584,"median":-38.307101,"eighty":-32.29343,"marketCap":201683285},{"date":"2021-07-23","current":-32.731802,"twenty":-55.950895,"median":-36.540142,"eighty":-32.426846,"marketCap":195081541},{"date":"2021-07-30","current":-30.701064,"twenty":-54.861592,"median":-35.683959,"eighty":-31.801171,"marketCap":182978343},{"date":"2021-08-06","current":-30.257994,"twenty":-54.401409,"median":-35.427145,"eighty":-31.125673,"marketCap":180337645},{"date":"2021-08-13","current":-22.113138,"twenty":-53.380326,"median":-35.055685,"eighty":-30.686295,"marketCap":169143396},{"date":"2021-08-20","current":-18.134562,"twenty":-52.808577,"median":-34.734848,"eighty":-30.547239,"marketCap":138711262},{"date":"2021-08-27","current":-23.543638,"twenty":-51.934884,"median":-34.553094,"eighty":-30.2621,"marketCap":180085287},{"date":"2021-09-03","current":-21.830019,"twenty":-51.63647,"median":-34.004385,"eighty":-29.866616,"marketCap":166977813},{"date":"2021-09-10","current":-20.921056,"twenty":-51.104358,"median":-33.811785,"eighty":-29.763523,"marketCap":160025154},{"date":"2021-09-17","current":-19.356447,"twenty":-50.507592,"median":-33.72871,"eighty":-23.209855,"marketCap":148057460},{"date":"2021-09-24","current":-17.940848,"twenty":-50.0977,"median":-33.451791,"eighty":-22.083336,"marketCap":137229548},{"date":"2021-10-01","current":-16.09312,"twenty":-49.378648,"median":-32.787186,"eighty":-21.645246,"marketCap":123096272},{"date":"2021-10-08","current":-13.79836,"twenty":-48.842921,"median":-32.38764,"eighty":-20.041894,"marketCap":105543655},{"date":"2021-10-15","current":-13.545042,"twenty":-47.591697,"median":-32.177965,"eighty":-19.326645,"marketCap":103606029},{"date":"2021-10-22","current":-15.184156,"twenty":-44.493144,"median":-31.510627,"eighty":-18.820009,"marketCap":116143612},{"date":"2021-10-29","current":-14.971519,"twenty":-42.758824,"median":-31.144134,"eighty":-18.268671,"marketCap":114517146},{"date":"2021-11-05","current":-14.543412,"twenty":-42.16739,"median":-30.783862,"eighty":-18.057076,"marketCap":111242557},{"date":"2021-11-12","current":-11.785515,"twenty":-41.656517,"median":-30.627219,"eighty":-16.67426,"marketCap":110701340},{"date":"2021-11-19","current":-11.190777,"twenty":-41.444646,"median":-30.586219,"eighty":-15.443434,"marketCap":105114970},{"date":"2021-11-26","current":-10.765965,"twenty":-41.153826,"median":-30.524667,"eighty":-15.011304,"marketCap":101124705},{"date":"2021-12-03","current":-9.273052,"twenty":-40.769832,"median":-30.263126,"eighty":-14.901037,"marketCap":87101775},{"date":"2021-12-10","current":-9.697864,"twenty":-40.614757,"median":-30.137996,"eighty":-14.716264,"marketCap":91092040},{"date":"2021-12-17","current":-8.119989,"twenty":-40.24184,"median":-29.851847,"eighty":-14.22751,"marketCap":76271057},{"date":"2021-12-23","current":-9.151677,"twenty":-39.898461,"median":-29.778485,"eighty":-14.030817,"marketCap":85961700},{"date":"2021-12-31","current":-8.374877,"twenty":-39.710156,"median":-29.015625,"eighty":-13.774518,"marketCap":78665216},{"date":"2022-01-07","current":-8.171232,"twenty":-39.252317,"median":-22.70918,"eighty":-13.5212,"marketCap":76752379},{"date":"2022-01-14","current":-7.989109,"twenty":-38.266486,"median":-22.209995,"eighty":-11.707835,"marketCap":75041702},{"date":"2022-01-21","current":-6.54427,"twenty":-38.104027,"median":-21.98648,"eighty":-11.020852,"marketCap":61470330},{"date":"2022-01-28","current":-5.73079,"twenty":-37.180964,"median":-21.830019,"eighty":-10.620315,"marketCap":53829306},{"date":"2022-02-04","current":-5.524384,"twenty":-35.899319,"median":-20.950858,"eighty":-9.843514,"marketCap":51890538},{"date":"2022-02-11","current":-5.281554,"twenty":-35.881369,"median":-19.997191,"eighty":-9.564352,"marketCap":49609635},{"date":"2022-02-18","current":-4.68662,"twenty":-35.683959,"median":-19.468204,"eighty":-9.151677,"marketCap":44021424},{"date":"2022-02-25","current":-4.905167,"twenty":-35.655196,"median":-19.095678,"eighty":-8.816682,"marketCap":46074236},{"date":"2022-03-04","current":-4.832318,"twenty":-35.500855,"median":-18.849811,"eighty":-8.469356,"marketCap":45389965},{"date":"2022-03-11","current":-3.838673,"twenty":-35.404992,"median":-18.440033,"eighty":-8.377085,"marketCap":47898958},{"date":"2022-03-18","current":-4.094584,"twenty":-35.168688,"median":-18.223968,"eighty":-8.190926,"marketCap":51092222},{"date":"2022-03-25","current":-4.551569,"twenty":-35.067209,"median":-18.134562,"eighty":-7.9813,"marketCap":56794479},{"date":"2022-04-01","current":-4.414474,"twenty":-34.998397,"median":-17.806739,"eighty":-7.073639,"marketCap":55083807},{"date":"2022-04-08","current":-3.756416,"twenty":-34.806847,"median":-16.659359,"eighty":-6.204308,"marketCap":46872556},{"date":"2022-04-14","current":-3.482225,"twenty":-34.72931,"median":-16.301735,"eighty":-5.920197,"marketCap":43451202},{"date":"2022-04-22","current":-3.098358,"twenty":-34.657798,"median":-15.184156,"eighty":-5.670082,"marketCap":38661305},{"date":"2022-04-29","current":-2.879005,"twenty":-34.581814,"median":-15.020245,"eighty":-5.478246,"marketCap":35924222},{"date":"2022-05-06","current":-2.769328,"twenty":-34.456166,"median":-14.94574,"eighty":-5.310694,"marketCap":34555680},{"date":"2022-05-13","current":-2.003871,"twenty":-34.163888,"median":-14.878685,"eighty":-5.05815,"marketCap":31817456},{"date":"2022-05-20","current":-2.169142,"twenty":-34.002839,"median":-14.752026,"eighty":-4.844835,"marketCap":34441635},{"date":"2022-05-27","current":-2.176324,"twenty":-33.902348,"median":-14.580665,"eighty":-4.626514,"marketCap":34555680},{"date":"2022-06-03","current":-2.434898,"twenty":-33.817324,"median":-14.237941,"eighty":-4.492371,"marketCap":38661305},{"date":"2022-06-10","current":-2.715019,"twenty":-33.769325,"median":-14.066579,"eighty":-4.410209,"marketCap":43109066},{"date":"2022-06-17","current":-2.38462,"twenty":-33.739787,"median":-13.880316,"eighty":-4.319081,"marketCap":37862989},{"date":"2022-06-24","current":-2.944862,"twenty":-33.713941,"median":-13.783459,"eighty":-4.118347,"marketCap":46758511},{"date":"2022-07-01","current":-2.38462,"twenty":-33.643788,"median":-13.559943,"eighty":-3.866092,"marketCap":37862989},{"date":"2022-07-08","current":-2.485176,"twenty":-33.599481,"median":-13.51524,"eighty":-3.756416,"marketCap":39459621},{"date":"2022-07-15","current":-2.269698,"twenty":-33.304101,"median":-11.785515,"eighty":-3.62846,"marketCap":36038267},{"date":"2022-07-22","current":-2.327159,"twenty":-33.008721,"median":-11.22719,"eighty":-3.463945,"marketCap":36950628},{"date":"2022-07-29","current":-2.19069,"twenty":-32.787186,"median":-10.966233,"eighty":-3.116637,"marketCap":34783770},{"date":"2022-08-05","current":-2.513906,"twenty":-32.731802,"median":-10.765965,"eighty":-2.94127,"marketCap":39915802},{"date":"2022-08-12","current":-2.369501,"twenty":-32.452984,"median":-10.371496,"eighty":-2.888144,"marketCap":45726624},{"date":"2022-08-19","current":-1.978533,"twenty":-32.322296,"median":-9.843514,"eighty":-2.860251,"marketCap":38181731},{"date":"2022-08-26","current":-1.990381,"twenty":-32.177965,"median":-9.637176,"eighty":-2.779662,"marketCap":38410364},{"date":"2022-09-02","current":-2.008152,"twenty":-32.177965,"median":-9.479389,"eighty":-2.679106,"marketCap":38753313},{"date":"2022-09-09","current":-2.049618,"twenty":-31.882584,"median":-9.273052,"eighty":-2.612619,"marketCap":39553529},{"date":"2022-09-16","current":-1.777126,"twenty":-31.778465,"median":-8.927133,"eighty":-2.564697,"marketCap":34294968},{"date":"2022-09-23","current":-1.463167,"twenty":-31.354465,"median":-8.739002,"eighty":-2.498104,"marketCap":28236190},{"date":"2022-09-30","current":-1.475014,"twenty":-31.207278,"median":-8.515854,"eighty":-2.472247,"marketCap":28464823},{"date":"2022-10-07","current":-1.380234,"twenty":-31.154609,"median":-8.414062,"eighty":-2.410477,"marketCap":26635758},{"date":"2022-10-14","current":-1.18475,"twenty":-31.070289,"median":-8.376257,"eighty":-2.383874,"marketCap":22863312},{"date":"2022-10-21","current":-1.18475,"twenty":-30.888924,"median":-8.219798,"eighty":-2.366779,"marketCap":22863312},{"date":"2022-10-28","current":-1.19956,"twenty":-30.74526,"median":-8.177302,"eighty":-2.332598,"marketCap":23149103},{"date":"2022-11-04","current":-1.18475,"twenty":-30.704756,"median":-7.989109,"eighty":-2.268262,"marketCap":22863312},{"date":"2022-11-11","current":-0.982108,"twenty":-30.641988,"median":-7.738926,"eighty":-2.226603,"marketCap":23973258},{"date":"2022-11-18","current":-0.98683,"twenty":-30.623139,"median":-6.568553,"eighty":-2.207222,"marketCap":24088514},{"date":"2022-11-25","current":-0.973845,"twenty":-30.622119,"median":-6.337865,"eighty":-2.187817,"marketCap":23771560},{"date":"2022-12-02","current":-1.038768,"twenty":-30.57904,"median":-6.05861,"eighty":-2.171771,"marketCap":25356331},{"date":"2022-12-09","current":-1.133202,"twenty":-30.541076,"median":-5.876487,"eighty":-2.146158,"marketCap":27661452},{"date":"2022-12-16","current":-0.963221,"twenty":-30.522618,"median":-5.700436,"eighty":-2.044879,"marketCap":23512234},{"date":"2022-12-23","current":-1.114315,"twenty":-30.382719,"median":-5.597233,"eighty":-2.00644,"marketCap":27200427},{"date":"2022-12-30","current":-1.510936,"twenty":-30.282201,"median":-5.512242,"eighty":-1.983272,"marketCap":36881936},{"date":"2023-01-06","current":-1.067098,"twenty":-30.2621,"median":-5.41511,"eighty":-1.948914,"marketCap":26047867},{"date":"2023-01-13","current":-1.067098,"twenty":-30.239533,"median":-5.305837,"eighty":-1.937067,"marketCap":26047867},{"date":"2023-01-20","current":-1.067098,"twenty":-30.165688,"median":-5.269412,"eighty":-1.931143,"marketCap":26047867},{"date":"2023-01-27","current":-0.982108,"twenty":-30.110304,"median":-5.050865,"eighty":-1.853108,"marketCap":23973258},{"date":"2023-02-03","current":-1.048212,"twenty":-29.870308,"median":-4.879173,"eighty":-1.605337,"marketCap":25586843},{"date":"2023-02-10","current":-0.977386,"twenty":-29.851847,"median":-4.747328,"eighty":-1.480938,"marketCap":23858002},{"date":"2023-02-17","current":-0.925448,"twenty":-29.850284,"median":-4.624687,"eighty":-1.427624,"marketCap":22590185},{"date":"2023-02-24","current":-0.691463,"twenty":-29.792845,"median":-4.539264,"eighty":-1.380234,"marketCap":19116174},{"date":"2023-03-03","current":-0.671478,"twenty":-29.74856,"median":-4.460173,"eighty":-1.350616,"marketCap":18563684},{"date":"2023-03-10","current":-0.59154,"twenty":-29.297133,"median":-4.41092,"eighty":-1.241662,"marketCap":16353721},{"date":"2023-03-17","current":-0.587543,"twenty":-28.913312,"median":-4.377915,"eighty":-1.213184,"marketCap":16243223},{"date":"2023-03-24","current":-0.6435,"twenty":-24.603931,"median":-4.285951,"eighty":-1.204298,"marketCap":17790197},{"date":"2023-03-31","current":-0.635506,"twenty":-22.876072,"median":-4.094584,"eighty":-1.196586,"marketCap":17569201},{"date":"2023-04-06","current":-0.571556,"twenty":-22.530367,"median":-3.902651,"eighty":-1.18475,"marketCap":15801231},{"date":"2023-04-14","current":-0.631509,"twenty":-22.348575,"median":-3.847812,"eighty":-1.176457,"marketCap":17458702},{"date":"2023-04-21","current":-0.631509,"twenty":-22.190624,"median":-3.756416,"eighty":-1.136035,"marketCap":17458702},{"date":"2023-04-28","current":-0.611525,"twenty":-22.068435,"median":-3.669588,"eighty":-1.107705,"marketCap":16906212},{"date":"2023-05-05","current":-0.575553,"twenty":-21.976049,"median":-3.591901,"eighty":-1.091651,"marketCap":15911729},{"date":"2023-05-12","current":-0.645498,"twenty":-21.904524,"median":-3.482225,"eighty":-1.080319,"marketCap":17845446},{"date":"2023-05-19","current":-0.649677,"twenty":-21.8479,"median":-3.422817,"eighty":-1.070403,"marketCap":20331654},{"date":"2023-05-26","current":-0.57906,"twenty":-21.645246,"median":-3.116637,"eighty":-1.067098,"marketCap":18121691},{"date":"2023-06-02","current":-0.564937,"twenty":-21.290602,"median":-2.980774,"eighty":-1.057655,"marketCap":17679699},{"date":"2023-06-09","current":-0.6179,"twenty":-20.968739,"median":-2.932987,"eighty":-1.044434,"marketCap":19337171},{"date":"2023-06-15","current":-0.600245,"twenty":-20.921056,"median":-2.919439,"eighty":-1.034046,"marketCap":18784680},{"date":"2023-06-23","current":-0.473135,"twenty":-20.241568,"median":-2.883574,"eighty":-1.018937,"marketCap":14806748},{"date":"2023-06-30","current":-0.430764,"twenty":-20.026993,"median":-2.869865,"eighty":-0.989663,"marketCap":13480770},{"date":"2023-07-07","current":-0.459011,"twenty":-19.913745,"median":-2.851348,"eighty":-0.982108,"marketCap":14364755},{"date":"2023-07-14","current":-0.49432,"twenty":-19.705131,"median":-2.822757,"eighty":-0.977386,"marketCap":15469736},{"date":"2023-07-21","current":-0.480196,"twenty":-19.490556,"median":-2.763721,"eighty":-0.967943,"marketCap":15027744},{"date":"2023-07-28","current":-0.45548,"twenty":-19.341546,"median":-2.697062,"eighty":-0.963221,"marketCap":14254257},{"date":"2023-08-04","current":-0.441357,"twenty":-19.207436,"median":-2.650375,"eighty":-0.95,"marketCap":13812265},{"date":"2023-08-11","current":-0.416641,"twenty":-18.903456,"median":-2.603688,"eighty":-0.926392,"marketCap":13038778},{"date":"2023-08-18","current":-0.350788,"twenty":-18.873653,"median":-2.577395,"eighty":-0.820525,"marketCap":11602302},{"date":"2023-08-25","current":-0.371693,"twenty":-18.83491,"median":-2.513906,"eighty":-0.685068,"marketCap":12293748},{"date":"2023-09-01","current":-0.396711,"twenty":-18.775306,"median":-2.49595,"eighty":-0.671478,"marketCap":13121212},{"date":"2023-09-08","current":-0.375267,"twenty":-18.596494,"median":-2.485176,"eighty":-0.653892,"marketCap":12411957},{"date":"2023-09-15","current":-0.382415,"twenty":-18.432582,"median":-2.463628,"eighty":-0.647497,"marketCap":12648375},{"date":"2023-09-22","current":-0.375267,"twenty":-18.361057,"median":-2.434898,"eighty":-0.647497,"marketCap":12411957},{"date":"2023-09-27","current":-0.332236,"twenty":-18.319334,"median":-2.424124,"eighty":-0.647097,"marketCap":10988719},{"date":"2023-10-06","current":-0.297676,"twenty":-18.238869,"median":-2.391802,"eighty":-0.639503,"marketCap":9845637},{"date":"2023-10-13","current":-0.31987,"twenty":-18.197146,"median":-2.38462,"eighty":-0.635506,"marketCap":10579716},{"date":"2023-10-20","current":-0.300214,"twenty":-18.152443,"median":-2.373845,"eighty":-0.631509,"marketCap":9929566},{"date":"2023-10-27","current":-0.293209,"twenty":-18.134562,"median":-2.369878,"eighty":-0.631509,"marketCap":9697876},{"date":"2023-11-03","current":-0.271479,"twenty":-18.134562,"median":-2.348707,"eighty":-0.623515,"marketCap":8979164},{"date":"2023-11-10","current":-0.214438,"twenty":-17.940848,"median":-2.330558,"eighty":-0.619518,"marketCap":7092547},{"date":"2023-11-17","current":-0.268324,"twenty":-17.806739,"median":-2.284063,"eighty":-0.615522,"marketCap":7801801},{"date":"2023-11-24","current":-0.225636,"twenty":-17.38951,"median":-2.262516,"eighty":-0.611525,"marketCap":6560606},{"date":"2023-12-01","current":-0.219132,"twenty":-16.844132,"median":-2.23375,"eighty":-0.607528,"marketCap":6371471},{"date":"2023-12-08","current":-0.195186,"twenty":-16.614656,"median":-2.212237,"eighty":-0.602874,"marketCap":5675219},{"date":"2023-12-15","current":-0.20287,"twenty":-16.52525,"median":-2.203715,"eighty":-0.59911,"marketCap":5898635},{"date":"2023-12-22","current":-0.199211,"twenty":-16.176566,"median":-2.19069,"eighty":-0.595537,"marketCap":5792246},{"date":"2023-12-29","current":-0.215473,"twenty":-15.902386,"median":-2.179915,"eighty":-0.59154,"marketCap":6265083},{"date":"2024-01-05","current":-0.215473,"twenty":-15.616286,"median":-2.176324,"eighty":-0.583546,"marketCap":6265083},{"date":"2024-01-12","current":-0.227588,"twenty":-15.184156,"median":-2.169142,"eighty":-0.575553,"marketCap":6617346},{"date":"2024-01-19","current":-0.217912,"twenty":-15.136473,"median":-2.154777,"eighty":-0.57191,"marketCap":6336008},{"date":"2024-01-26","current":-0.20413,"twenty":-15.076869,"median":-2.114779,"eighty":-0.557875,"marketCap":5935279},{"date":"2024-02-02","current":-0.231491,"twenty":-14.993423,"median":-2.043694,"eighty":-0.501381,"marketCap":6730827},{"date":"2024-02-09","current":-0.243931,"twenty":-14.972324,"median":-2.011125,"eighty":-0.494052,"marketCap":7092547},{"date":"2024-02-16","current":-0.247997,"twenty":-14.950896,"median":-2.00305,"eighty":-0.485846,"marketCap":7210756},{"date":"2024-02-23","current":-0.304914,"twenty":-14.932329,"median":-1.984457,"eighty":-0.475253,"marketCap":8865684},{"date":"2024-03-01","current":-0.278488,"twenty":-14.901037,"median":-1.948914,"eighty":-0.459011,"marketCap":8097324},{"date":"2024-03-08","current":-0.390435,"twenty":-14.877195,"median":-1.940029,"eighty":-0.451949,"marketCap":9456729},{"date":"2024-03-15","current":-0.486178,"twenty":-14.817591,"median":-1.937067,"eighty":-0.451949,"marketCap":11775725},{"date":"2024-03-22","current":-0.462661,"twenty":-14.763947,"median":-1.932624,"eighty":-0.451949,"marketCap":11206115},{"date":"2024-03-28","current":-0.451577,"twenty":-14.728184,"median":-1.922257,"eighty":-0.451601,"marketCap":10937645},{"date":"2024-04-05","current":-0.457442,"twenty":-14.66262,"median":-1.853108,"eighty":-0.451601,"marketCap":11079693},{"date":"2024-04-12","current":-0.445712,"twenty":-14.588115,"median":-1.655689,"eighty":-0.451601,"marketCap":10795598},{"date":"2024-04-19","current":-0.410525,"twenty":-14.442085,"median":-1.587565,"eighty":-0.446181,"marketCap":9943314},{"date":"2024-04-26","current":-0.38648,"twenty":-14.248371,"median":-1.495937,"eighty":-0.441357,"marketCap":9360920},{"date":"2024-05-03","current":-0.431168,"twenty":-14.162243,"median":-1.463167,"eighty":-0.433831,"marketCap":10443321},{"date":"2024-05-10","current":-0.475036,"twenty":-14.102788,"median":-1.412815,"eighty":-0.432294,"marketCap":11505835},{"date":"2024-05-17","current":-0.639125,"twenty":-14.048698,"median":-1.380234,"eighty":-0.43552,"marketCap":12358119},{"date":"2024-05-24","current":-0.61697,"twenty":-13.980153,"median":-1.37476,"eighty":-0.437826,"marketCap":11929739},{"date":"2024-05-31","current":-0.779486,"twenty":-13.902667,"median":-1.323959,"eighty":-0.438113,"marketCap":15072137},{"date":"2024-06-07","current":-0.838241,"twenty":-13.834122,"median":-1.249912,"eighty":-0.43968,"marketCap":16208235},{"date":"2024-06-14","current":-0.845669,"twenty":-13.79836,"median":-1.232357,"eighty":-0.441357,"marketCap":16351847},{"date":"2024-06-21","current":-0.683888,"twenty":-13.774518,"median":-1.222913,"eighty":-0.441357,"marketCap":13223668},{"date":"2024-06-28","current":-0.714039,"twenty":-13.732795,"median":-1.214369,"eighty":-0.441357,"marketCap":13806661},{"date":"2024-07-05","current":-0.711465,"twenty":-13.589745,"median":-1.208445,"eighty":-0.441357,"marketCap":13756880},{"date":"2024-07-12","current":-0.838315,"twenty":-13.559943,"median":-1.202522,"eighty":-0.441357,"marketCap":16209657},{"date":"2024-07-15","current":-0.815592,"twenty":-13.556963,"median":-1.19956,"eighty":-0.442228,"marketCap":15770290},{"date":"2024-08-02","current":-0.856699,"twenty":-13.553983,"median":-1.199412,"eighty":-0.443099,"marketCap":16565132},{"date":"2024-08-09","current":-0.742791,"twenty":-13.533121,"median":-1.196598,"eighty":-0.446181,"marketCap":14362609},{"date":"2024-08-16","current":-0.794193,"twenty":-13.061245,"median":-1.187712,"eighty":-0.44712,"marketCap":15356517},{"date":"2024-08-23","current":-1.15671,"twenty":-12.142357,"median":-1.18475,"eighty":-0.449067,"marketCap":17347177},{"date":"2024-08-30","current":-1.876643,"twenty":-11.785515,"median":-1.187712,"eighty":-0.451507,"marketCap":28144012},{"date":"2024-09-06","current":-2.192608,"twenty":-11.766095,"median":-1.196569,"eighty":-0.451589,"marketCap":32882545},{"date":"2024-09-13","current":-1.914942,"twenty":-11.59617,"median":-1.199263,"eighty":-0.451699,"marketCap":28718380},{"date":"2024-09-20","current":-1.608551,"twenty":-11.219907,"median":-1.206964,"eighty":-0.451949,"marketCap":24123439},{"date":"2024-09-27","current":-1.503229,"twenty":-11.156792,"median":-1.208445,"eighty":-0.451949,"marketCap":22543928},{"date":"2024-10-04","current":-1.445781,"twenty":-10.999005,"median":-1.224565,"eighty":-0.452015,"marketCap":21682376},{"date":"2024-10-11","current":-1.148965,"twenty":-10.88734,"median":-1.232357,"eighty":-0.452921,"marketCap":17231028},{"date":"2024-10-18","current":-1.225563,"twenty":-10.785385,"median":-1.22589,"eighty":-0.45548,"marketCap":18379763},{"date":"2024-10-25","current":-1.378758,"twenty":-10.736835,"median":-1.235137,"eighty":-0.455755,"marketCap":20677233},{"date":"2024-10-31","current":-1.359609,"twenty":-10.620315,"median":-1.249912,"eighty":-0.456855,"marketCap":20390049},{"date":"2024-11-08","current":-1.417057,"twenty":-10.45039,"median":-1.266908,"eighty":-0.457442,"marketCap":21251601},{"date":"2024-11-15","current":-1.665999,"twenty":-10.292602,"median":-1.32131,"eighty":-0.459011,"marketCap":24984990},{"date":"2024-11-22","current":-2.095324,"twenty":-10.231915,"median":-1.363998,"eighty":-0.459011,"marketCap":30170577},{"date":"2024-11-29","current":-2.383432,"twenty":-9.921194,"median":-1.369183,"eighty":-0.461931,"marketCap":34319032},{"date":"2024-12-06","current":-2.160803,"twenty":-9.756124,"median":-1.373971,"eighty":-0.462708,"marketCap":31113408},{"date":"2024-12-13","current":-2.213186,"twenty":-9.705147,"median":-1.378758,"eighty":-0.463189,"marketCap":31867672},{"date":"2024-12-20","current":-2.121516,"twenty":-9.600764,"median":-1.380234,"eighty":-0.463306,"marketCap":30547709},{"date":"2024-12-27","current":-2.60606,"twenty":-9.569207,"median":-1.380234,"eighty":-0.463517,"marketCap":37524655},{"date":"2025-01-03","current":-2.789401,"twenty":-9.530367,"median":-1.398005,"eighty":-0.464624,"marketCap":40164581},{"date":"2025-01-10","current":-2.907263,"twenty":-9.476962,"median":-1.417057,"eighty":-0.466165,"marketCap":41861676},{"date":"2025-01-17","current":-2.553677,"twenty":-9.428412,"median":-1.440994,"eighty":-0.466978,"marketCap":36770391},{"date":"2025-01-24","current":-2.776305,"twenty":-9.273052,"median":-1.445781,"eighty":-0.46876,"marketCap":39976015},{"date":"2025-01-31","current":-2.671539,"twenty":-9.151677,"median":-1.455356,"eighty":-0.469171,"marketCap":38467486},{"date":"2025-02-07","current":-2.737018,"twenty":-9.018164,"median":-1.469718,"eighty":-0.473135,"marketCap":39410316},{"date":"2025-02-14","current":-2.592964,"twenty":-8.836102,"median":-1.480938,"eighty":-0.473135,"marketCap":37336089},{"date":"2025-02-21","current":-2.317953,"twenty":-8.836102,"median":-1.503229,"eighty":-0.473248,"marketCap":33376201},{"date":"2025-02-28","current":-2.121516,"twenty":-8.758422,"median":-1.503229,"eighty":-0.474684,"marketCap":30547709},{"date":"2025-03-07","current":-2.001275,"twenty":-8.680742,"median":-1.510936,"eighty":-0.476339,"marketCap":27907784},{"date":"2025-03-14","current":-1.879576,"twenty":-8.578787,"median":-1.515197,"eighty":-0.47949,"marketCap":26210689},{"date":"2025-03-21","current":-1.825488,"twenty":-8.491203,"median":-1.551103,"eighty":-0.480196,"marketCap":25456424},{"date":"2025-03-28","current":-1.487434,"twenty":-8.453115,"median":-1.55589,"eighty":-0.482636,"marketCap":20742272},{"date":"2025-04-04","current":-1.446868,"twenty":-8.42079,"median":-1.528001,"eighty":-0.483668,"marketCap":20176573},{"date":"2025-04-11","current":-1.27108,"twenty":-8.411844,"median":-1.519998,"eighty":-0.485697,"marketCap":17725214},{"date":"2025-04-17","current":-1.568567,"twenty":-8.391098,"median":-1.525203,"eighty":-0.486826,"marketCap":21873668},{"date":"2025-04-25","current":-1.744355,"twenty":-8.375981,"median":-1.528001,"eighty":-0.487258,"marketCap":24325028},{"date":"2025-05-02","current":-1.852532,"twenty":-8.369248,"median":-1.55589,"eighty":-0.487258,"marketCap":25833557}],"updateTime":1746407340986}}}